Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin ... Our most recently signed SPL, Kamau Therapeutics, brings our total number of SPLs to 29. We are very ...

Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce ... Our most recently signed SPL, Kamau Therapeutics, brings our total number of SPLs to 29. We are very excited ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has ... by introducing a gene known as BCL11A which down-regulates the production of the adult form of the oxygen-carrying ...

Exagamglogene autotemcel is under clinical development by CRISPR Therapeutics and currently in Phase III for ... vivo by CRISPR/Cas9 at the erythroid-specific enhancer region of the BCL11A gene. It is ...

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...